Skip to main navigation

Investors + Newsroom
Culture + Careers

Who We Are

Who We Are
Science & Innovation

Science & Innovation
Therapeutic Pipeline

Therapeutic Pipeline
Patients & Families

Patients & Families

Search
Investors + Newsroom

Investors + Newsroom
Culture + Careers

Events

Presentations

REGENXBIO Corporate Presentation – April 2024 2.2 MB

REGENXBIO New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial Presentation; MDA 2024 1.3 MB

REGENXBIO Rare Disease Program Update Presentation 704.9 KB

REGENXBIO Interim Data Update from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery Presentation; Hawaiian Eye and Retina 2024 990 KB

REGENXBIO Interim Data Update from Phase II ALTITUDE® Trial of ABBV-RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery Presentation - AAO 2023 956.8 KB

Upcoming Events

More events are coming soon.

Past Events

Apr 03, 2024 at 9:50 AM EDT

Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days

Click here for webcast

Mar 18, 2024

UBS Virtual CNS Day

CLICK HERE FOR WEBCAST

Mar 13, 2024 at 4:05 PM EDT

Barclays 26th Annual Global Healthcare Conference

Link below for fireside chat

Click here for webcast

Mar 12, 2024

Leerink Partners 2024 Global Biopharma Conference

Mar 05, 2024 at 8:30 AM EST

REGENXBIO New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial; MDA 2024

Click here for webcast

Supporting Materials

REGENXBIO New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial Presentation; MDA 2024 1.3 MB

Feb 27, 2024 at 4:30 PM EST

Q4 2023 REGENXBIO Inc. Earnings Conference Call

Click here for webcast

Feb 07, 2024 at 4:30 PM EST

REGENXBIO Rare Disease Program Update

Click here for webcast

Supporting Materials

REGENXBIO Rare Disease Program Update Presentation 704.9 KB

Jan 16, 2024 at 4:30 PM EST

REGENXBIO Interim Data Update from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery; Hawaiian Eye and Retina 2024

Click here for webcast

Supporting Materials

REGENXBIO Interim Data Update from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery Presentation; Hawaiian Eye and Retina 2024 990 KB

Nov 29, 2023 at 12:30 PM EST

Piper Sandler 35th Annual Healthcare Conference

Click here for webcast

Nov 14, 2023 at 3:00 PM EST

Stifel 2023 Healthcare Conference

Click here for webcast

Pagination

Current page 1
Page 2
Next page
Last page

Contact Us

Stay connected on REGENXBIO programs and our commitment to patients.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

Contact Us

Terms and Conditions

Privacy Policy

© 2024 Regenxbio Inc. • "NAV®" is a registered trademark of REGENXBIO Inc. • All Rights Reserved